Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...
Clinical trial approval / initiation
Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...
Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...
CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin
China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...
Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA
Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...
Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...
Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...
Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy
China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...
Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...
Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia
China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...
Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...
CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...
Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors
China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...
Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...